Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia

Journal of the American College of Cardiology

Volumn 55, Issue 11, 2010, Pages 1121-1126

  Avis, Hans J ^a   Hutten, Barbara A ^a   Gagné, Claude ^b   Langslet, Gisle ^c   McCrindle, Brian W ^d   Wiegman, Albert ^a   Hsia, Judith ^e   Kastelein, John J P ^a   Stein, Evan A ^f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LAVAL UNIVERSITY   (Canada)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e ASTRAZENECA   (United Kingdom)

^f Metabolic and Atherosclerosis Research Center   (United States)

Author keywords

drugs; genetics; hypercholesterolemia; pediatrics; prevention

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEVELOPMENTAL DISORDER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; FEMALE; GROWTH DISORDER; HUMAN; INFLUENZA; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; MULTICENTER STUDY; MYALGIA; MYOPATHY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; CHILD; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77749310839     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.10.042     Document Type: Article

References (21)

1. Leigh S.E., Foster A.H., Whittall R.A., Hubbart C.S., and Humphries S.E. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet 72 (2008) 485-498
2. Marks D., Thorogood M., Neil H.A., and Humphries S.E. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168 (2003) 1-14
3. Wiegman A., de Groot E., Hutten B.A., et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 363 (2004) 369-370
4. de Jongh S., Lilien M.R., op't Roodt J., Stroes E.S., Bakker H.D., and Kastelein J.J. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 40 (2002) 2117-2121
5. Burke G.L., Evans G.W., Riley W.A., et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) study. Stroke 26 (1995) 386-391
6. Avis H.J., Vissers M.N., Stein E.A., et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 27 (2007) 1803-1810
7. Wiegman A., Hutten B.A., de Groot E., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292 (2004) 331-337
8. McCrindle B.W., Urbina E.M., Dennison B.A., et al., American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 115 (2007) 1948-1967
9. Daniels S.R., and Greer F.R. Lipid screening and cardiovascular health in childhood. Pediatrics 122 (2008) 198-208
10. McCrindle B.W., Ose L., and Marais A.D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 143 (2003) 74-80
11. Jones P.H., Davidson M.H., Stein E.A., et al., STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92 (2003) 152-160
12. American Academy of Pediatrics. National Cholesterol Education Program: report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89 (1992) 525-584
13. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 449-502
14. Centers for Disease Control and Prevention. National Center for Health Statistics. National Health and Nutrition Examination Survey. Z-score data files. http://www.cdc.gov/nchs/about/major/nhanes/growthcharts/zscore/zscore.ht m Accessed May 12, 2009
15. Stein E.A., Strutt K., Southworth H., Diggle P.J., and Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 92 (2003) 1287-1293
16. Stein E.A., Illingworth D.R., Kwiterovich Jr. P.O., et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia. A randomized controlled trial. JAMA 281 (1999) 137-144
17. De Jongh S., Ose L., Szamosi T., et al., Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 106 (2002) 2231-2237
18. Thompson P.D., Zmuda J.M., Domalik L.J., Zimet R.J., Staggers J., and Guyton J.R. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46 (1997) 1206-1210
19. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., and Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40 (2002) 567-572
20. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 2 (1969) 1380-1382
21. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504